Sign In
Buy RETA
$172.36
+0 (+0%)
At Close: Dec 22, 2023
SHERMAN, Texas, Jan. 8, 2024 /PRNewswire/ -- TO: All persons and entities who, during the period between November 14, 2016 through December 8, 2021 inclusive, purchased or otherwise acquired the comm
Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
10:08am, Thursday, 21'st Sep 2023
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global, biopharmaceutical company focused on developing
The 7 Most Promising Momentum Stocks to Own Now
08:30am, Thursday, 31'st Aug 2023
Today's volatile market makes momentum investing a compelling strategy for those comfortable with daily turbulence. Unlike value investing, which is rooted in purchasing undervalued assets, momentum i
The 3 Most Promising Pharma Stocks to Own Now
05:20am, Wednesday, 30'th Aug 2023
It is remarkable that day after day there are pharmaceutical companies working hard, researching and developing high-tech medicines for the improvement of human health and the treatment of severe dise
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Reata Pharma
CPMG Inc Acquires Significant Stake in Reata Pharmaceuticals Inc
10:03pm, Tuesday, 01'st Aug 2023
CPMG Inc (Trades, Portfolio), a prominent investment firm, recently expanded its portfolio with the acquisition of a substantial number of shares in Reata Pharmaceuticals Inc. This article provides an
Biogen to buy rare-disease drugmaker Reata in $7.3B deal
05:26pm, Friday, 28'th Jul 2023
Yahoo Finance Health Care Reporter Anjalee Khemlani reports on Biogen buying rare-disease drugmaker Reata for $7.3 billion.
Biogen Buys Reata Pharmaceuticals, Expanding Its Lineup of Rare Disease Drugs
04:40pm, Friday, 28'th Jul 2023
Biogen said it was buying Reata Pharmaceuticals for $7.3 billion, expanding its rare disease treatment portfolio.
Why Biogen Agreed to Acquire Reata for $7.3 Billion
02:45pm, Friday, 28'th Jul 2023
Biogen agreed to acquire Reata Pharmaceuticals for $7.3 billion, including debt, to expand its rare disease treatments. Michelle Davis reports on "Bloomberg Markets.
Reata Pharmaceuticals stock opened 50% up on Friday: what happened?
12:49pm, Friday, 28'th Jul 2023
Shares of Reata Pharmaceuticals Inc (NASDAQ: RETA) opened more than 50% up this morning after Biogen Inc (NASDAQ: BIIB) said it will buy the pharma company for $7.3 billion. Why is Biogen making this
Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?
10:23am, Friday, 28'th Jul 2023
Reata Pharmaceuticals (NASDAQ: RETA ) stock is soaring higher on Friday as investors react to an acquisition deal with Biogen (NASDAQ: BIIB ). That deal has Biogen offering to buy shares of RETA stock
Biogen to acquire Reata Pharmaceuticals for $7.3B
10:06am, Friday, 28'th Jul 2023
Biogen Inc (NASDAQ:BIIB) said it has agreed to acquire Reata Pharmaceuticals for about $7.3 billion in cash as it bulks up its neuromuscular and rare disease portfolio. Shares of Reata shot up 52% to
Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition
09:45am, Friday, 28'th Jul 2023
Biogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.
Reata Stock Surges. Biogen Is Buying It for $7.3 Billion in Cash.
08:02am, Friday, 28'th Jul 2023
Biogen will acquire Reata for $172.50 a share in cash, expanding its portfolio of neuromuscular disease treatments.
Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion in cash
07:16am, Friday, 28'th Jul 2023
Biogen Inc. BIIB, -0.93% said Friday it has agreed to acquire Reata Pharmaceuticals Inc. RETA, +2.32% for $7.3 billion in cash. Reata “has made significant advancements developing therapeutics that
